Recent studies have demonstrated that ACPAs are the strongest serum marker associated with future RA progression in patients with recent-onset arthritis [4,5] and radiographic progression in ACPA-positive patients with early RA is greater than that in ACPA-negative patients [6-8]. Here, PRTN3 is linked to arthritic joint disease.